Wave Life Sciences (WVE) Assets Average (2015 - 2026)
Wave Life Sciences' (WVE) quarterly Assets Average came in at $570.9 million in Q2 2026, up 111.18% YoY from $270.3 million in Q2 2025, and down 6.56% on a QoQ basis from $611.0 million in Q1 2026.
Wave Life Sciences (WVE) Assets Average (2015 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 12 years of Assets Average data on file, last reported at $570.9 million in Q2 2026.
- Quarterly Assets Average rose 111.18% year-over-year to $570.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $570.9 million (up 111.18% YoY) and the FY2025 annual result came in at $495.4 million, up 57.97% from the prior year.
- Assets Average slipped to $570.9 million in Q2 2026, from $611.0 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $611.0 million in Q1 2026 to a low of $163.9 million in Q4 2022.
- A 5-year average of $290.1 million and a median of $247.7 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average fell 28.27% — and 2026, when it soared 111.18%.
- Tracing WVE's Assets Average over 5 years: stood at $163.9 million in 2022, then surged by 44.82% to $237.4 million in 2023, then jumped by 49.67% to $355.4 million in 2024, then increased by 23.8% to $439.9 million in 2025, then increased by 29.78% to $570.9 million in 2026.
- The last three Assets Average figures came in at $570.9 million (Q2 2026), $611.0 million (Q1 2026), and $439.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | 570.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 570.93 Mn |
| Mar 31, 2026 | 611.02 Mn |
| Dec 31, 2025 | 439.94 Mn |
| Sep 30, 2025 | 246.87 Mn |
| Jun 30, 2025 | 270.35 Mn |
| Mar 31, 2025 | 320.28 Mn |
| Dec 31, 2024 | 355.36 Mn |
| Sep 30, 2024 | 283.66 Mn |
| Jun 30, 2024 | 222.04 Mn |
| Mar 31, 2024 | 255.11 Mn |
| Dec 31, 2023 | 237.43 Mn |
| Sep 30, 2023 | 214.95 Mn |
| Jun 30, 2023 | 248.63 Mn |
| Mar 31, 2023 | 206.83 Mn |
| Dec 31, 2022 | 163.95 Mn |
| Sep 30, 2022 | 197.42 Mn |
| Jun 30, 2022 | 190.34 Mn |
| Mar 31, 2022 | 187.18 Mn |
| Dec 31, 2021 | 203.76 Mn |
| Sep 30, 2021 | 203.46 Mn |